Update on New Generation of Precision Medicine Protocols in Treating AML
Posted: Friday, March 20, 2020
Pamela S. Becker, MD, PhD, of the University of Washington Institute for Stem Cell and Regenerative Medicine (ISCRM), Seattle, and colleagues, presented the results of a multiomic precision medicine clinical trial in acute leukemia at the 2019 American Society for Hematology (ASH) Annual Meeting & Exposition (Abstract 1269; ClinicalTrials.gov identifier NCT02551718). The correlative analyses from this clinical trial, which feature responses to study-guided treatment, are expected to form the basis of new treatment algorithms.
“To get a more complete picture, we are looking at gene expression, mutational data, bioinformatics, and drug sensitivity data, so we can make the best treatment choices possible for individual patients,” shared Dr. Becker in an ISCRM press release.
With an original enrollment of 25 patients, the study was later expanded to provide an option for patients with refractory disease. A total of 44 patients with AML were included; 7 had favorable-risk, 13 had intermediate-risk, and 24 had adverse-risk disease. Therapy based on the high throughput sensitivity screening was received by more than half of these patients (n = 25). “Of the 22 patients who had circulating peripheral blasts, 21 (95%) had a reduction, including 7 eradication of circulating peripheral blasts following therapy,” reported the investigators. The median survival after initiation of the protocol therapy was 70 days (range, 19–811 days), and the overall response rate was 31%.
“We are moving from a one-size-fits-all model to customized, individual treatment approaches. That’s a paradigm shift in cancer treatment,” concluded Dr. Becker.
Disclosure: The authors’ disclosure information can be found at ashpublications.org.